MedTrace Logo

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

NCT01196676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2011-08-01

No results posted yet for this study

Summary

This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.

Conditions

Interventions

DRUG

AZD4451

1 mg capsules, 5 mg capsules, and 25 mg capsules

DRUG

Placebo

1 mg capsules, 5 mg capsules, and 25 mg capsules

Sponsors & Collaborators

Principal Investigators

  • Mark Smith · AstraZeneca, LP, 1800 Concord Pike, Wilmington, DE

  • Ralph Schutz · Quintiles Phase I Services, 6700 West 115th Street, Overland Park, Kansas 66211

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196676 on ClinicalTrials.gov